July 28, 2025 (press release) — Answer ALS, a large-scale research initiative headquartered in New Orleans and Washington, D.C., has announced the launch of the Louisiana AI Drug Development Infrastructure for ALS (LADDIA), a groundbreaking collaborative initiative aimed at accelerating AI-powered drug discovery for ALS and other neurodegenerative diseases.
LADDIA brings together leading institutions and innovators, including GATC Health — a tech-bio innovator using validated AI models to accelerate drug discovery from large-scale multiomics data — Pennington Biomedical Research Center, and Tulane University to harness the power of artificial intelligence and one of the largest ALS datasets in the world.